these cytokines in lymphocyte development is illustrated by primary immunodeficiency that arises from inactivating mutations of γc (encoded by IL2RG), termed X-linked severe combined immunodeficiency (X-SCID). Many γc cytokines also have been implicated in diverse auto immune diseases. IL-2 is the prototypic T-cell growth factor and has both proinflammatory and anti-inflammatory effects. This cytokine is important for effector T cells, upregulating production of other cytokines and augmenting the cytolytic activity of CD8 + T cells and natural killer (NK) cells. Blockade of the IL-2 receptor with daclizumab is approved for the treatment of transplant rejection and seems to be efficacious in multiple sclerosis (MS) 9, 10 . IL-4 is found at elevated levels in the synovial fluid of patients with early RA but is absent in late disease 11 ; generally, though, IL-4 is thought to be more important in driving allergic diseases. Both IL-7 and IL-15 are important for lymphocyte homeo stasis and T-cell memory 11, 12 IL-15 also regulates NK cells, whereas IL-7 is important for the homeostasis of other innate lymphoid cells 13 . Thymic stromal lympho poietin (TSLP) shares the IL-7 receptor-α chain as a receptor component; it has a role in T-cell development and allergy 12 . IL-9 is involved in atopy and IBD 14 . IL-21 promotes differentiation of follicular helper T (T FH ) cells, which act on B cells in germinal centres to promote anti body class-switching 15 . Inactivating mutations of IL21 and IL21R result in immunodeficiency 16 . Because of their role in class switching, T FH cells are thought to be important for diverse autoantibodylinked autoimmune diseases including RA and systemic lupus erythematosus (SLE). Levels of IL-21 are increased in the synovium and serum of patients with RA 17 . Targeting IL-21 has been investigated in phase I trials of RA and Crohn disease, although results have not yet been reported 18 . The common β-chain cytokines include IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF). Encoded by CSF2, GM-CSF is a proinflammatory growth factor with a key role in the generation, survival, and activation of myeloid cells. It is produced by pathogenic T cells, and a body of data points to its importance in driving autoimmunity 19 . GM-CSF blockade has been effective for RA in phase II clinical trials 20 . IL-6 is the prototypic proinflammatory cytokine, which, like a number of related cytokines, signals through the gp130 receptor subunit (encoded by IL6ST). Among its many actions, IL-6 drives the production of TNF and IL-1, and induces the differentiation of type 17 helper T (T H 17) cells (FIG. 2) . These cells are the major producers of IL-17, which acts synergistically with TNF to promote activation of chondrocytes and fibroblast-like synovio cytes, production of metalloproteinases, and joint destruction in RA 1 . Tocilizumab and other agents in development target IL-6 (TABLE 1) . Clinical trials are on going for multiple indications beyond RA, such as vasculitis and myositis (ClinicalTrials.gov identifiers NCT01450137 and NCT02043548, respectively). Other gp130 cytokines include IL-11, IL-27, and IL-31. IL-11 is involved in haematopoiesis and bone remodelling. IL-31 is produced by T H 2 cells, mast cells and other leukocytes; this cytokine has a role in skin barrier function and myeloid development 21 . IL-27 is also a gp130 cytokine but primarily limits inflammation, including antagonizing IL-17 production [22] [23] [24] (see below). Related to the gp130 cytokines is the dimeric cytokine family, which includes IL-12, IL-23, and IL-35. IL-12 promotes the differentiation of IFN-γ-producing T H 1 cells, whereas IL-23 promotes IL-17 production and generation of T H 17 cells. IL-23 is important in the pathogenesis of psoriasis, IBD, and spondyloarthritis 2 . Targeting IL-23 and IL-12 with ustekinumab is effective for psoriasis 25 and has shown promise as a treatment for IBD 26 .
Type II cytokines in autoimmunity
The type II cytokines comprise a large group of >30 signalling molecules including the type I, II, and III IFNs (IFN-α, IFN-β, IFN-γ, IL-28, and IL-29) and IL-10-related cytokines (IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26) . A large body of evidence implicates type I IFNs in the development of autoimmunity: multi ple rheumatologic diseases including RA, SLE, systemic sclerosis (SSc), and myositis are characterized by acti vation of type I IFN signalling 27, 28 . Mendelian disorders associated with upregulation of type I IFN signalling also present with severe inflammation and autoimmunity 29 . Paradoxically, though, IFN-β is an approved therapy for MS (as discussed below).
IFN-γ, the type II IFN, also contributes to the pathogenesis of autoimmune diseases, although the relative contribution of T H 1 versus T H 17 cells is the subject of ongoing research. T H 1 cells, the main producers of IFN-γ, have been implicated in the development of RA and in animal models of collagen-induced arth ritis (CIA) 11 . However, mice lacking the Ifng and Ifngr1 genes are not protected from CIA, and IFN-γ deficiency can even exacerbate the disease. IL-20 is produced by keratin ocytes, neutrophils and fibroblast-like synovio cytes 30 , has been implicated in synoviocyte migration and osteoclast formation, and is upregulated in RA synovia 31 . Phase II clinical trials targeting IL-20 have shown encouraging results in the treatment of RA 31 . IL-20 produced by keratinocytes has been implicated in the pathogenesis of psoriatic skin disease 30 . Other type II cytokines, such as IL-10 and IL-22, have different actions, bringing us to the 'good guy' cytokines.
Key points
• Cytokines are major drivers of autoimmunity, and targeting cytokines has revolutionized the treatment of rheumatologic diseases • Despite their success, biologic agents that target key cytokines are not completely effective in all patients • Type I and II cytokines signal through the JAK-STAT pathway, and pharmacological inhibition of this signal transduction pathway with small molecules can block the actions of these cytokines • JAK inhibitors, or Jakinibs, are effective for rheumatoid arthritis and other immune-mediated diseases • Many of the adverse effects of Jakinibs can be linked to action of the cytokines that are blocked • Jakinibs are currently being investigated for a number of new indications, and second-generation selective Jakinibs are being developed and tested Nature Reviews | Rheumatology 
Anti-inflammatory actions of cytokines
Although cytokines are clearly positive effectors of immune responses and drivers of autoimmunity, many type I and II cytokines also have anti-inflammatory actions that need to be considered in the treatment of autoimmune disease. IL-2 is a prime example: the importance of this cytokine in promoting immune tolerance through upregulation of FOXP3 protein would seem to indicate that IL-2 inhibition might induce, rather than treat, autoimmunity 32 , but the efficacy of targeting IL-2 in MS provides a very different view 9, 10 . While daclizumab is efficacious in the treatment of MS, this therapy can be complicated by rash and alopecia, indicative of exacerbation of autoimmunity 9, 10, 33 . IL-2 is not alone in having complex actions; many cytokines have both proinflammatory and anti-inflammatory properties. Other cytokines with anti-inflammatory properties include IL-10, IL-22, and IL-35. IL-10 is perhaps the best characterized of these anti-inflammatory cytokines: it suppresses T-cell-dendritic cell/macrophage interactions 11, 34 and negatively regulates NLRP3 inflammasome activation Figure 1 | Cytokines are grouped into superfamilies based on shared structural elements of the receptors they bind. The major cytokine families are: the type I/II cytokines, the TNF family, the IL-1 family, the IL-17 cytokines, the stem cell factor/receptor tyrosine kinase (STF/RTK) cytokines, the transforming growth factor (TGF)-β family cytokines, and chemokines. The type I/II cytokine families signal through Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. When a cytokine binds to its cognate receptor, the receptor becomes activated. JAKs autophosphorylate and transphosphorylate, causing STATs to be recruited to the activated receptor where they, in turn, are phosphorylated. The STATs then dimerize and translocate to the nucleus where they initiate transcription. FDA-approved medications blocking the different classes of cytokine receptor are denoted in pink boxes. C/EBP, CCAAT/enhancer binding protein β; Co-SMAD, common-mediator SMAD; CREB, cyclic AMP response element-binding protein; DAG, diacylglycerol; ERK, extracellular signal-regulated kinase; GSK3β, glycogen synthase kinase 3β; IκB, inhibitor of κB; IKK, IκB kinase; IP3, inositol 1,4,5-trisphosphate; MAP, mitogen-activated protein; NFκB, nuclear factor κB; PK, protein kinase; PLC, phospholipase C. 36 . IL-22 is involved in epithelial barrier function and can augment IL-17 function; elevated levels of this cytokine are associated with increased disease activity in RA 37 . IL-27 can enhance T H 1 cell differentiation, but also antagonizes IL-2 production, promotes IL-10 production, and inhibits T H 17 cell responses [22] [23] [24] . IL-27 is found at increased levels in the serum and synovial fluid of patients with RA, but whether its role is predominantly proinflammatory or anti-inflammatory is unclear 24, 38 . However, recent data suggest that IL-27 prevents the development of ectopic lymphoid-like structures in arthritic joints 39 . Even the IFNs, which are crucial for immune responses to viral infections and heavily implicated in the pathogenesis of auto immune diseases, have immunosuppressive effects; in fact, IFN-β is an approved treatment for MS 40 . Other 'good guy' functions of cytokines include the role of growth factors and hormones that regulate homeostasis and haemato poiesis. Erythropoietin, thrombopoietin, granulocyte colony-stimulating factor (G-CSF), growth hormone, and leptin, among others, signal via JAKs 41 . All these factors must be considered carefully when designing small-molecule inhibitors of JAKs, which will simultaneously and potently block the actions of multiple factors.
Overview of JAK-STAT signalling
The receptors bound by type I and type II cytokines lack intrinsic catalytic activity; rather, these receptors have an extracellular cytokine-binding domain and a cytoplasmic domain that associates with JAKs. There are four JAKs -JAK1, JAK2, JAK3, and TYK2 (tyro sine kinase 2) -each associates with different cytokine receptors 8, 41 (TABLE 1) . JAKs are kinases or phospho transferases, meaning they transfer phosphate from ATP to tyro sine residues of their substrates, an important activation event within cells. One crucial attribute of JAKs is their ability to deposit a phosphate on themselves (autophosphorylation) or on other JAKs (transphosphorylation). Cytokines induce JAK enzymatic activity by binding the extracellular portion of their cognate receptors. This modification enables a variety of signalling molecules to recognize the 'activated' receptor.
When one considers the number of cytokines that signal through JAKs, it is not surprising that mutations and polymorphisms of genes encoding these kinases have been linked to diseases of immunity (TABLE 2) . For example, JAK3 mediates signalling for all the γc cytokines; thus, inactivating mutations of JAK3 recapitulate the phenotype of γc deficiency and cause SCID 42, 43 . TYK2 loss-of-function causes a milder immuno deficiency 44 . A large body of evidence from genome-wide association studies has implicated JAKs in the pathogenesis of autoimmune diseases. TYK2 is linked to SLE and Crohn disease 45, 46 , and JAK2 polymorphisms are associated with Behçet disease 47 . STATs comprise an important class of molecules that transmit signals from type I and II cytokine receptors to the nucleus. STATs reside in the cytosol before activation. Upon stimulation by cytokines, STATs bind active phosphorylated receptors and are, in turn, phosphorylated by JAKs. This modification causes STATs to translocate to the nucleus, where they bind DNA and activate . G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IBD, inflammatory bowel disease; IFN, interferon; IGF-1, insulin-like growth factor 1; JAK, Janus kinase; Jakinib, JAK inhibitor; MS, multiple sclerosis; N/A, not applicable; NK cell, natural killer cell; pJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; sJIA, systemic-onset juvenile idiopathic arthritis; SLE, systemic lupus erythematosus; STAT, signal transducer and activator of transcription; T FH cell, follicular helper T cell; T H cell, helper T cell. *IL-13 does not share the common γc but shares the IL-4 receptor α subunit (IL-4Rα); dupilumab targets IL-4Rα and therefore blocks both IL-4 and IL-13. ‡ Both IL-12 and IL-23 are composed of the p40 subunit; ustekinumab, which targets p40, blocks both cytokines. Nature Reviews | Rheumatology (TABLE 3) .
Loss-of-function mutations in STAT1 or STAT2 cause immunodeficiency 41 . STAT1 gain-of-function mutations lead to chronic mucocutaneous candidiasis via inhibition of IL-17 production 41 . Autoimmunity has also been reported in association with STAT1 gain-of-function mutations, likely due to increased signalling downstream of IFN-γ, IL-21, and IL-6 (REF. 48 ). Dominant negative mutations of STAT3 cause hyper IgE syndrome (also known as Job syndrome), which is characterized by dermatitis, elevated levels of IgE, susceptibility to bacterial pulmonary infection, connective tissue disorders, and bone abnormalities 49 . Conversely, gain-of-function STAT3 mutations cause early-onset lymphoproliferative disease and autoimmunity 50 . STAT5 deficiency manifests with immunodeficiency and autoimmunity, as well as dwarfism attributable to the role of STAT5 in mediating growth-hormone signalling 51, 52 . Genome-wide associ ation studies have established links between STAT3 and Behçet disease 47 , Crohn disease 53 , and psoriasis 53 , whereas STAT4 polymorphisms are associated with RA and SLE 54 . Finally, polymorphisms in STAT6, which mediates IL-4 signalling, are associated with atopy and asthma 55 . Thus, a large body of evidence points to a critical role for JAKs and STATs in the pathogenesis of rare and common disorders of human immunity.
Jakinibs in autoimmune diseases
The success of 'biologic therapies' in treating autoimmunity notwithstanding, the prospect of new alternatives -namely blocking key cytokines by targeting their signal transduction pathways with small molecules -offers a novel and exciting opportunity for treating disease (FIG. 2) . This possibility was recognized in 1995 (REF. 43 ), but the development of JAK inhibitors (Jakinibs) faced several important challenges. One important consideration is that most Jakinibs act as competitive inhibitors of ATP 41 (FIG. 3) and all kinases have some degree of homology. Despite such challenges, differences in kinase structure can be capitalized upon to generate inhibitors that exhibit some degree of specificity. First-generation Jakinibs (tofacitinib, ruxolitinib, baricitinib and oclacitinib) inhibit more than one JAK but seem to have reasonable kinome selectivity. Interestingly, none of the first-generation Jakinibs are good TYK2 inhibitors 56 .
Tofacitinib
The first Jakinib developed for the treatment of autoimmune diseases was tofacitinib, which inhibits JAK1, JAK3 and, to a lesser extent, JAK2 (REF. 57 ). After promising results in preclinical and early-phase clinical trials for various immune-mediated diseases 41 , tofacitinib was extensively evaluated in pivotal trials in 2012. Multiple phase II and III studies demonstrated that tofacitinib was effective for RA as monotherapy or in combination with DMARDs, for treatment-naive or DMARD-refractory disease, and even for disease refractory to treatment with biologic agents [58] [59] [60] [61] [62] . Tofacitinib was superior to metho trexate in the treatment of naive patients 63 and as effective as adalimumab 62 . Two clinical trials assessing MRI and radiographic responses in nearly 1,000 patients indicated that tofacitinib halts structural damage and erosive disease 61, 63, 64 . Based on these findings, tofacitinib was approved by the US FDA for the treatment of patients with RA with inadequate response to methotrexate.
Tofacitinib has also been found to be effective in the treatment of psoriasis and psoriatic arthritis 65 , being noninferior to etanercept [65] [66] [67] . However, the FDA has declined to approve tofacitinib for psoriasis. This may be because higher doses of tofacitinib (10 mg twice daily) than the approved dose for RA (5 mg twice daily) were required for optimal efficacy. The higher dose (10 mg twice daily) was not approved by the FDA because of concerns regarding adverse events 68 . Studies also indicate that continuous therapy results in more durable remission, although up to 60% of patients can recapture a response when treated intermittently 69 . Tofacitinib is also an efficacious treatment for ulcerative colitis 70 and possibly for Crohn disease, although results in the latter are inconsistent 71 . In prophylaxis of kidney transplant rejection, tofacitinib preserves renal function better than standardof-care with calcineurin inhibitors, by preventing tubular atrophy and interstitial fibrosis 72 .
Ruxolitinib and baricitinib
The JAK1 and JAK2 inhibitor ruxolitinib was actually the first FDA-approved Jakinib, for the treatment of myeloproliferative disease 41 . However, ruxolitinib seems to be efficacious in models of preclinical arth ritis 73 , and results of a phase II trial in RA are promising (ClinicalTrials.gov identifier NCT00550043).
Another JAK1 and JAK2 inhibitor, baricitinib, has shown efficacy in the treatment of RA, in which setting -like tofacitinib -it is effective in patients with disease refractory to treatment with DMARDs and TNF inhibitors [74] [75] [76] [77] . Baricitinib halts radiographic disease progression, with significant differences in erosions and joint-space narrowing, particularly at the higher dose of 4 mg twice daily, and to a lesser degree with 2 mg twice daily [74] [75] [76] [77] .
Oclacitinib
Oclacitinib is a nonselective Jakinib approved for the treatment of eczema in dogs. Orally administered Jakinibs are not currently being tested for the treatment of allergic diseases in humans; however, the efficacy of oclacitinib in canine atopic dermatitis 78 demonstrates that inhibition of JAKs can disrupt key signalling pathways that drive allergic inflammation 79 . These findings have paved the way for clinical trials of topical tofacitinib for the treatment of atopic skin disease in humans (ClinicalTrials.gov identifier NCT02001181).
Adverse effects of Jakinibs
As with other effective therapies in autoimmune disease, Jakinibs are not without side effects. Many of the adverse effects of Jakinibs can, like their therapeutic efficacy, be directly traced to their mechanism of action: blocking JAK-dependent cytokine signalling. Because more patients have been treated with tofa citinib than other agents, we know the most about this drug; how ever, the adverse effect profile of baricitinib seems comparable [74] [75] [76] [77] .
Infection
An obvious concern with the use of any immunomodulatory drug is the risk of infection, and in clinical trials increased rates of infections have been demonstrated in tofacitinib-treated patients. These infections were mainly upper respiratory tract infections, urinary tract infections, and viral gastroenteritis. However, serious cases of tuberculosis, fungal infection, Pneumocystis jirovecii pneumonia, and bacterial pneumonia were reported as well 65, 72, [80] [81] [82] [83] . Given the broad range of cytokines that can be affected by tofacitinib, this outcome was not unexpected.
The risk of infection with tofacitinib use is compar able to that with other biologic agents 82, 83 , with one exception: the risk of varicella zoster virus (VZV) infection seems to be increased 82, 84 . This increase could be attributable to the effects of tofacitinib on IFN or IL-15 signalling, the latter being a key cytokine for NK-cell homeostasis 85 . However, NK cell counts are only moderately reduced in tofacitinib-treated patients and do not correlate with infection risk 86, 87 . Tofacitinib-treated patients also have impaired responses to vaccination 88 , so clinicians are encouraged to immunize patients against pneumococcus and VZV before initiating this therapy, as is also recommended with other biologic agents.
In renal transplant recipients, higher rates of BK polyomavirus infection were seen in those treated with tofacitinib than with ciclosporin, although the drugs were used in the setting of combination immunosuppressive therapy 89 . While most of these infections do not result in nephropathy, a trend towards higher rates of BK polyomavirus-associated nephropathy in tofacitinib-treated patients was observed 89 . Clinical trials and long-term extension studies have not revealed similar issues in patients with RA 82, 83 , but clearly this potential risk must be monitored as new Jakinibs emerge for various clinical indications and as part of combined treatment regimens.
Lipid effects
Increases in levels of total cholesterol, LDL cholesterol, and HDL cholesterol have been noted in clinical trials of tofacitinib 41, 82, 83 This side effect is also seen with IL-6 receptor (IL-6R) blocker tocilizumab 90, 91 IL-6 promotes insulin resistance and redistributes fatty acids from the blood to peripheral tissues, thereby decreasing serum lipids 91, 92 . Thus, treatment-induced changes in lipid levels may or may not correlate with rates of cardiovascular disease. The results of clinical trials and long-term extension data do not indicate an increased risk of cardiovascular disease with tofacitinib use 82, 92 . On the contrary, tofacitinib can improve arterial stiffness, suggesting that it might improve cardiovascular outcomes in patients with RA 93 . In this context, tofacitinib-induced hypercholesterolaemia could be cardioprotective. Indeed, patients with RA commonly have low total, HDL, and LDL cholesterol levels and a discordantly increased risk of cardio vascular disease 92 . Moreover, Jakinibs alter lipoprotein kinetics 94 and increase LDL particle size 94 . Jakinibs also confer metabolic properties of brown fat key domains including a tyrosine kinase domain, pseudokinase domain,  FERM (band four-point-one, ezrin, radixin, moesin) domain, and SH2 (Src homology 2) domain. The tyrosine kinase domain binds ATP hydrolysing it to ADP and catalyses both autophosphorylation and other substrates including signal transducers and activators of transcription (STATs). JAK, Janus kinase (JAK) inhibitors (Jakinibs) bind to the pocket ordinarily occupied by ATP, thereby preventing JAKs from using ATP and phosphorylating their substrates.
to white adipo cytes by uncoupling the respiratory chain and increasing mitochondrial activity 95 , a novel and provocative mech anism by which JAK blockade might reduce cardio vascular risk. Needless to say, the metabolic effects of JAK blockade are complex and deserve further attention.
Because all first-generation Jakinibs inhibit JAK2, which mediates erythropoietin, thrombopoietin, IL-11, G-CSF and GM-CSF signalling, patients treated with these agents can develop cytopenias, especially anaemia; generally, this effect is not necessarily a cause for discontinuation of treatment. Other adverse effects reported in clinical trials include minimal elevations in serum transaminases 41 and reductions in glomerular filtration rate 80 . Neither of these laboratory abnormalities seems to indicate any substantial end-organ damage, with the possible exception of BK polyomavirus-associated nephropathy 82 .
Other considerations
Although the adverse events attributed to Jakinibs in clinical trials for rheumatologic diseases indicate an acceptable safety profile, several additional factors warrant consideration. Cytokines such as IL-10, IL-22 and IL-27 have important anti-inflammatory actions; other cytokines such as IL-2 have both inflammatory and immunosuppressive actions. Whether suppression of these anti-inflammatory actions will be clinically relevant in the context of inflammatory cytokine blockade remains to be determined.
Finally, the potential role of JAK inhibition in tumour development warrants discussion. Because IFNs, IL-12, and other cytokines contribute to the elimination and destruction of tumours, prolonged blockade of JAK-STAT signalling might promote malignancy 96 . However, as is the case with biologic therapies, whether Jakinib-treated patients are truly at increased risk of cancer is unclear. In RA trials, the risk of malignancy in tofacitinib-treated patients was not significantly increased 82 . Although tofacitinib is associated with an increased risk of nonmelanoma skin cancer, the effect size is similar to that seen with other biologic agents such as TNF inhibitors 81 . When Jakinibs have been used for transplant-rejection prophylaxis in combination with other immunosuppressive drugs, the risk of developing post-transplant lymphoproliferative disease (PTLD) is increased 72 .
New applications for Jakinibs
The future of therapies that target JAKs and the cytokines that signal through them is only starting to emerge (TABLE 4) . One need only consider the example of tocilizumab to see the potential applicability of JAK blockade to a wide variety of immune-mediated diseases. Initially used for the treatment of RA, tocilizumab is now approved for use in polyarticular juvenile idio pathic arthritis (JIA) and systemic-onset JIA 97, 98 and has been used successfully to treat large-vessel vasculitis 99 , polymyalgia rheumatica 100 , amyloid A (AA) amyloid osis 101 , spondyloarthritis 102 , SSc 103 , and myositis 104 , among other rheumatologic diseases. As IL-6 is clearly blocked by existing Jakinibs, these diseases should be reasonable settings in which to test JAK blockade.
Alopecia areata is characterized by an IFN-γ and γc cytokine gene signature 88 . Tofacitinib, ruxolitinib, and baricitinib have all been used successfully to treat alo pecia areata and alopecia universalis [105] [106] [107] [108] , and clinical trials in these diseases are ongoing (ClinicalTrials.gov identifiers NCT02299297, NCT02197455, NCT02312882, NCT01950780). Preliminary evidence indicates that tofacitinib could be equally effective in the treatment of vitiligo 109 , and that inhibition of JAK-STAT signalling causes hair growth through initiation of anagen 110 . The presence of the type I IFN gene signature in SLE, myositis, primary SjÖgren syndrome, and SSc, and perhaps a subset of RA patients, suggests that Jakinibs might be useful in these settings 27, 28, 111, 112 . A case of refractory dermatomyositis was indeed reported to respond to treatment with ruxolitinib 113 . The potential for Jakinibs to treat IFNmediated diseases has also been suggested by preliminary data in patients with interferonopathies -monogenic diseases characterized by uncontrolled upregulation of type I IFNs 114 . A 'compassionate use' study of baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) and STINGassociated vasculopathy with onset in infancy (SAVI) is ongoing 115 (ClinicalTrials.gov identifier NCT01724580). An important consideration involves the optimal dosing and route of administration for Jakinibs. Although the current paradigm of continuous low-level dosing is comparable to that of DMARDs and other maintenance therapies, it is possible that Jakinibs might be most effective when used in high doses to induce remission followed by tapering to much lower doses. Moreover, topical formulations of tofacitinib improve symptoms of dry eye disease 116 , and are being investigated for psoriasis and eczema (ClinicalTrials.gov identifiers NCT01831466, NCT02193815, NCT02001181, and NCT00678561). If these formulations prove as efficacious as systemic therapy, they could fundamentally alter the treatment of diseases that affect a single organ system -including pulmonary and gastrointestinal diseases.
Jakinibs: the next generation
The assessment of the adverse events associated with tofacitinib led the European Medical Agency to refuse marketing approval for tofacitinib for the treatment of RA. Other agencies had a different view of the relative risks and benefits of this drug. As with any immunomodulatory drug, the goal is to identify regimens that provide efficacy at the minimal effective dose. As more experience is gained with tofacitinib and other Jakinibs in a range of disorders, we should have a better understanding of the risks and benefits of these agents, and perhaps more insights into optimal dosing and regimens in real-world usage. Whether the assessment of the relative benefits and risks of baricitinib and other agents in development will or will not be viewed similarly to those of tofacitinib remains to be seen.
However, with the demonstrated efficacy of multiple first-generation Jakinibs that exhibit kinome selectivity but target multiple JAKs, the question naturally arises whether targeting a single JAK would be superior. Might such agents exhibit similar efficacy with fewer adverse events? Conversely, though, agents that block fewer JAKs by definition block fewer inflammatory cytokines, which could negatively affect their therapeutic efficacy. Indeed, development of second-generation Jakinibs with a greater degree of JAK selectivity is underway. Phase I and II trials seem to indicate that the JAK1 inhibitor filgotinib 117 and the JAK3 inhibitor decernotinib 118, 119 are effective for the treatment of RA. Several important questions will need to be answered as these and other selective Jakinibs emerge on the clinical scene. The apparent selectivity of these agents needs to be verified in vivo, by examining lymphoid, myeloid, and erythroid compartments for signs that other JAKs -especially JAK2 -are being affected. Furthermore, even if an inhibitor is exquisitely selective for one JAK over another, selecti vity is not necessarily ensured across the kinome. This was the case for a recently developed class of reversible covalent JAK3 inhibitors that also targeted several other tyrosine kinases 120 . At present, ~20 Jakinibs are in clinical trials for various auto immune conditions including autoinflammatory disease, RA, psoriasis and psoriatic arthritis, SLE, JIA, spondyloarthritis, discoid lupus, ulcerative colitis, atopic dermatitis, and diabetic nephro pathy (ClinicalTrials.gov identifiers NCT01458574, NCT01724580, NCT01687309, NCT01500551, NCT01597050, and NCT02001181).
Targeting STATs?
In principle, cytokine signalling could also by blocked by inhibiting STAT activation, interrupting STAT-receptor interactions, blocking STAT dimerization, or interfering with STAT-DNA binding 41, 121 . These strategies have been considered especially in cancer, in which constitutive JAK-STAT activation is a common event 41 . However, unlike JAKs, STATs are not enzymes, and generating drug candidates suitable for clinical use has been difficult owing to challenges of bioavail ability, in vivo efficacy, and selectivity; for instance, STAT3, a heavily investigated target in the treatment of solid-organ malignancy, has a high degree of homology with STAT1. Moreover, STATs represent convergent endpoints for multiple signalling pathways with critical roles in tumour prevention and host defence 122 . These issues must be considered if STATs are to be targeted in the treatment of rheumatologic diseases.
Conclusions
Cytokines that signal through JAKs and STATs are fundamental drivers of host defence, immunity, and inflammation. Advances in the understanding of cytokine biology, and of the links between cytokine regulation and autoimmunity, have sparked a revolution in the treatment of rheumatologic diseases over the past 15 years. However, the continuing burden of immune-mediated diseases clearly demonstrates that novel forms of therapy are needed. The emergence of small-molecule targeted therapies represents a new era owing to the ability of these agents to simultaneously block multiple signalling pathways. Tofacitinib is the first targeted small molecule to be approved for use in rheumatologic diseases and is likely to be joined by a number of other Jakinibs. A new chapter in the treatment of immune-mediated diseases has begun, in which the paradigm has been fundamentally shifted yet again. The next 5 years will be a crucial time, as we learn how to best use Jakinibs and other small-molecule inhibitors for the treatment of the vast array of autoimmune diseases encountered by clinicians.
